Public Policy Resources

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Integrating Randomized Controlled Trials for Drug and Biological Products into Routine Clinical Practice.

A coalition of 74 patient and provider groups has offered their support of H.R. 8412, the Clinical Trial Modernization Act, which would remove tax liabilities for financial support received while on clinical trials as well as create a safe harbor for sponsors offering such support.  

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies.

The House Energy and Commerce Committee sought community feedback on potential structural and policy changes at the National Institutes of Health.  ACS CAN offered suggestions related to NCI and the proposal's impacts on cancer research. 

Multi-Cancer Screening Tests Can Catch Cancer Early

Drug shortages have been a chronic issue for cancer patients, and ACS CAN has offered feedback to the Senate Finance Committee on their draft proposal to address root causes of the shortage.

The Clinical Trial Modernization Act (H.R. 8412) would increase access to clinical trials by allowing clinical trial sponsors to provide financial support to patients for costs associated with their trial participation, including medical cost-sharing like copays, and non-medical expenses such as travel, parking, food and lodging.

ACS CAN submitted comments on draft U.S. Food and Drug Administration (FDA) guidance on Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for Food and Drug Administration-Regulated Medical Products.